Database

In March 2025, psychedelic researchers published 138 studies and we've added 11 new papers to the database. This month featured psilocybin for alcoholism (AUD), microdosing for ADHD, long-term follow-up, and several investigations into how psychedelics work.

This study presents seven cryo-electron microscopy (cryo-EM) structures showing how different classes of psychedelic and non-psychedelic compounds interact with the serotonin (5-HT) 2A receptor—the primary target for classical psychedelics' therapeutic effects—revealing both shared and distinct binding patterns that could guide the development of new therapeutic compounds with improved side effect profiles.

This double-blind placebo-controlled trial (n=53) testing LSD microdosing (20μg; 2xp/w; 6w) for adults with moderate to severe ADHD found that while the treatment was safe and well-tolerated, it showed no advantage over placebo in reducing ADHD symptoms, with both groups showing similar improvements on standardised symptom measures.

This double-blind randomised clinical trial (n=37) found that a single dose of psilocybin (25mg) with brief psychotherapy did not significantly reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients.

This open-label, proof-of-concept trial (n=5) of psilocybin-assisted therapy for fibromyalgia finds the treatment to be well-tolerated, with only transient blood pressure elevations and headaches reported. Secondary outcomes show clinically meaningful improvements in pain severity, pain interference, and sleep disturbance one month after treatment, with all participants reporting some degree of symptom improvement.

Zagreb hosts 2nd Science of Psychedelics conference on Apr 5, 2025, bringing experts together to explore research and therapeutic applications of psychedelics.

This secondary analysis of an open-label waitlist-controlled clinical trial (n=27) finds no significant differences in depression, anxiety, and suicidality symptom improvements between treatment-resistant depression (TRD) patients who discontinued antidepressants before psilocybin-assisted psychotherapy (1-3x25mg; PAP/PAT) and those unmedicated at screening.

This systematic review (s=98) examining psychedelic-catalysed insight found that 86% of studies showed insight was linked to therapeutic improvement, with insight being dose-dependent and significantly higher than placebo in 93% of comparative studies, suggesting insight may be a key mechanism in psychedelic therapy.

This pre-print qualitative study (n=18) explores therapeutic touch in psychedelic-assisted therapy (PAT) for Generalised Anxiety Disorder (GAD). It finds that most participants valued touch during psilocybin dosing sessions, feeling it provided connection and helped manage intense emotional experiences, with some attributing therapeutic effects to it. The study emphasises the importance of a strong therapeutic relationship and recommends individualised use of touch, alongside further research on safety and therapist training.

This Phase III, placebo-controlled, randomised, quadruple-blind trial (n=220) will assess the efficacy, safety, and tolerability of CYB003, a deuterated psilocin analogue, as an adjunctive treatment for major depressive disorder (MDD). Participants will receive either 16 mg of CYB003 or a placebo in two dosing sessions, approximately three weeks apart, while continuing their current antidepressant medication and receiving psychological support.